We are live on ! Find out more
GBT

Global Blood Therapeutics, Inc.
GBT

Delisted

GBT was delisted on the 4th of October, 2022.

Back to rankings

2 hedge funds and large institutions have $42.1K invested in Global Blood Therapeutics, Inc. in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 239 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 247 → 2 (-245)

100% less funds holding in top 10

Funds holding in top 10: 21 → 0 (-21)

100% less capital invested

Capital invested by funds: $4.73B → $42.1K (-$4.73B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 239

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-245
Holders Change %
-99.19%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-21
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
239
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$428M
2
BlackRock
BlackRock
New York
-$323M
3
BBA
Baker Bros. Advisors
New York
-$254M
4
PCM
Pentwater Capital Management
Florida
-$218M
5
State Street
State Street
Massachusetts
-$162M
Name Holding Trade Value Shares
Change 		Change in
Stake
N
76
Natixis
France
– -$12M -176,600 Closed
FIM
77
Fernwood Investment Management
Massachusetts
– -$11.9M -174,724 Closed
AI
78
ArchPoint Investors
Florida
– -$11.5M -168,725 Closed
Ensign Peak Advisors
79
Ensign Peak Advisors
Utah
– -$11.5M -168,180 Closed
California Public Employees Retirement System
80
California Public Employees Retirement System
California
– -$10.8M -158,222 Closed
Wells Fargo
81
Wells Fargo
California
– -$10.5M -153,804 Closed
Bank of America
82
Bank of America
North Carolina
– -$10.2M -149,118 Closed
Swiss National Bank
83
Swiss National Bank
Switzerland
– -$9.98M -146,600 Closed
HM
84
Harvest Management
New York
– -$9.64M -141,500 Closed
WP
85
Woodline Partners
California
– -$9.11M -133,700 Closed
CS
86
Credit Suisse
Switzerland
– -$8.97M -131,712 Closed
KCM
87
Kynam Capital Management
New Jersey
– -$8.94M -131,220 Closed
Barclays
88
Barclays
United Kingdom
– -$8.88M -130,434 Closed
PCM
89
Prelude Capital Management
New York
– -$8.51M -125,029 Closed
HWAM
90
Hennion & Walsh Asset Management
New Jersey
– -$8.48M -124,483 Closed
FLC
91
Fifth Lane Capital
Texas
– -$7.99M -117,300 Closed
CCM
92
Crabel Capital Management
California
– -$7.67M -112,680 Closed
GLAM
93
Gardner Lewis Asset Management
Pennsylvania
– -$7.66M -112,500 Closed
Marshall Wace
94
Marshall Wace
United Kingdom
– -$7.05M -103,490 Closed
Rafferty Asset Management
95
Rafferty Asset Management
New York
– -$6.97M -102,397 Closed
PAMS
96
Pictet Asset Management (Switzerland)
Switzerland
– -$6.82M -100,199 Closed
AGC
97
Angelo Gordon & Co
New York
– -$6.81M -100,000 Closed
E
98
Ergoteles
New York
– -$6.54M -96,027 Closed
BHMP
99
Bardin Hill Management Partners
New York
– -$6.22M -91,416 Closed
RhumbLine Advisers
100
RhumbLine Advisers
Massachusetts
– -$6.08M -89,339 Closed
2 3
4
5 6

GBT Hedge Fund Activity: Q4 2022 in Review

2 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q4 2022, worth a combined $42.1K — down 100% from $4.73B a quarter earlier.

Sellers outnumbered buyers: 239 funds closed out of GBT and 0 opened new positions — a net loss of 239 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $428M sold.

  • 2 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q4 2022, down from 247 in Q3 2022.
  • Funds reported $42.1K of Global Blood Therapeutics, Inc. stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Global Blood Therapeutics, Inc. positions in Q4 2022 and 239 closed out, a net change of -239 holders.
  • The largest Global Blood Therapeutics, Inc. seller in Q4 2022 was Vanguard Group, an estimated $428M sold.

Based on aggregated 13F filings for Q4 2022.